《新股消息》瑞爾(06639.HK)一手中籤率80% 明日掛牌
瑞爾集團(06639.HK)公佈招股結果,每股發售價定爲14.62元,與招股價相同,香港公開發售部分錄得超額認購0.74倍,每手500股計,一手中籤率爲80%,認購兩手即1,000股穩獲一手。該股將於明日(22日)掛牌。聯席保薦人爲摩根士丹利及瑞銀集團。
是次招股引入5名基石投資者,包括OrbiMed Funds 、Hudson Bay、Harvest、Abax及現化牙科(03600.HK)旗下高鵬香港,合共認購3,473.65萬股公司股份,佔緊隨全球發售完成後已發行股本5.97%。
公司是次上市淨集約5.9億元,約75%擬用於業務擴張、在現有及新城市開設新的瑞爾及瑞泰醫院及診所;約15%將用於建設及優化信息技術基礎設施;及約10%將通過採取舉措用於營運資金,以繼續爲客戶提供優質的口腔醫療服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.